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Abstract
Background: Vitamin D binding protein (DBP) binds vitamin D and its plasma metabolites, including 25-
hydroxyvitamin D (25(OH)D), in the circulation. Only a small fraction circulates free (free 25(OH)D). Genetic variation
of the GC gene, encoding DBP, has been associated with 25(OH)D concentrations. The roles of DBP and free 25(OH)
D concentrations in the biological actions of vitamin D remain unclear.
Methods: We assessed the relationship between GC gene variants rs4588, rs7041, and rs705124, and serum total
25(OH)D, free and bioavailable 25(OH)D, and serum DBP and parathyroid hormone (PTH) concentrations in 622
Caucasian females (421) and males (201) aged 37–47 years. Concentrations of 25(OH)D, DBP, and PTH were measured
from fasting blood samples. Dietary intakes of vitamin D and Ca were evaluated using 1-month food use frequency
data, which were collected by a validated Food Frequency Questionnaire on vitamin D and calcium intakes. The
subjects filled in the questionnaire covering overall health, medications, use of vitamin D and calcium supplements,
and holidays in sunny locations. Three SNPs in the GC gene were genotyped: rs4588, rs7041, and rs705124. The SNPs
rs4588 and rs7041 combine to form six common diplotypes. Free and bioavailable 25(OH)D were calculated by using
specific binding coefficients. Differences among the diplo- and haplotypes of the GC gene in measures of 25(OH)D,
DBP, and PTH were tested by analysis of covariance (ANCOVA) using appropriate covariates.
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Results: We found significant variation among the SNPs rs4588 and rs7041 variants in DBP, total, free, and
bioavailable 25(OH)D, and PTH. DBP concentration was lowest in genotype GC2/2 in both diplotypes and
haplotypes (p = 0.039 and 0.039, respectively). The lowest 25(OH)D concentrations were found in diplotype
variants GC1S/2, GC1S/F, and GC2/2 (p = 0.033), but free and bioavailable 25(OH)D concentrations were highest
in the GC2/2 variant after corrected with a genotype-specific binding coefficient (p < 0.001 in both groups).
Surprisingly, one of the lowest PTH concentrations was also present in variant GC2/2 in diplotypes (p = 0.040
of the overall ANCOVA analysis of PTH). Among SNP rs705124, there was a difference only in PTH
concentrations (p = 0.013).
Conclusions: Our findings indicate that genetic variation of the DBP coding gene, and free concentrations of
25(OH)D may be relevant when vitamin D status, metabolism, and action are investigated.
Keywords: Vitamin D binding protein, PTH, 25(OH)D, Free 25(OH)
Background
Vitamin D, obtained from the diet or produced from 7-
dehydrocholesterol in the skin during UVB-exposure, is
hydroxylated into prohormone 25-hydroxyvitamin D
(25(OH)D) in the liver. Serum 25(OH)D is the bio-
marker most commonly used for describing vitamin D
status. The active metabolite, 1,25-dihydroxyvitamin D
(1,25(OH)2D3), is produced in the kidneys and probably
also in several other tissues, and has an important role
in regulating calcium homeostasis and skeletal mineral
balance as well as having roles in many other physio-
logical systems. Vitamin D binding protein (DBP) trans-
ports 25(OH)D from the liver to the kidneys and other
tissues. DBP binds 85–90 % of the total circulating
25(OH)D and 85 % of the total circulating 1,25(OH)2D3.
Albumin and lipoproteins bind the remaining 15 %, but
with a lower affinity. Less than 1 % of the vitamin D me-
tabolites are free in circulation [1]. In addition to being a
transport protein, DBP is suggested to have a role in
bone formation. In its deglycosylated form, DBP can act
as a macrophage activating factor and produce morpho-
logical changes in osteoclasts and also activate them,
which is correlated with enhanced bone resorption [2–4].
The DBP coding gene, GC gene, has two well-known mis-
sense variations in exon 11: a G >A substitution, which
results in p.T416K, and a C >A substitution, which results
in T420K, leading to a Threonine/Lysine amino acid
change [5]. Haplotypes of the nucleotide changes result in
the protein isoforms GC1S, GC2, and GC1F. Thus, the
two gene variants, rs4588 and rs7041, in general combine
to form six diplotypes: GC1S/1S, GC1S/2, GC1F/1 F,
GC1F/2, GC1F/1S, and GC2/2 [6, 7].
The free hormone hypothesis states that only hor-
mones not bound to binding protein can enter the cells
and have actions there [8]. Because the affinity of albu-
min to 25(OH)D is very weak, the bioavailable 25(OH)D
represents the sum of free and albumin bound fraction
of 25(OH)D. S25(OH)D is commonly known to enter
the cells in a 25(OH)D-DBP complex via a megalin-
mediated receptor. However, many tissues, especially
extra-renal tissues, do not express megalin, and in these
cases unbound free or bioavailable 25(OH)D might be
the form in which vitamin D enters the cells. Thus, these
metabolites have been suggested to be better markers of
vitamin D status/concentrations [9–11].
Several studies have reported an association between
GC genetic variation and serum 25(OH)D concentra-
tions. There is also evidence that DBP concentration and
affinity to 25(OH)D varies between the GC genotypes,
and this variation may be of importance when serum
25(OH)D concentrations are interpreted [6]. It is cur-
rently unclear whether the variation in DBP concentra-
tion results in a change in biologically available
25(OH)D (free 25(OH)D) [12].
PTH is a key regulator of calcium balance in the body,
and it correlates inversely with 25(OH)D. Increased con-
centrations of PTH affect bone negatively [13]. We hy-
pothesized that free and bioavailable 25(OH)D as well as
the genetic variation in the DBP could affect these asso-
ciations. The aim of this study was to examine the asso-
ciation between GC genotypes, DBP, serum total, free,
and bioavailable 25(OH)D, and PTH concentration in an
adult Caucasian population.
Methods
Study subjects and study design
The data for this study originates from the “Dietary phos-
phorus and health outcomes (PHOMI) study”, a cross-
sectional study of 653 individuals of Caucasian background
aged 37–47 years living in the Helsinki area (60°N, south-
ern Finland) who were derived from the Population Regis-
ter Center. The study design and methods are described in
detail in Itkonen et al. [14]. The final number of the sub-
jects was intended to be 800 persons in the original study
(400 females and 400 males). The number is based on a
power of 80 % (α = 0.05) to find a 4 % difference (standard
deviation, SD-0.050 g/cm2) in distal radius bone mineral
density between the highest and lowest phosphorus intake
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tertiles (data not shown), and taking into account the initial
dropout of 40 % (based on 1200 subjects).
The initial exclusion criterion was pregnancy. Subjects
visited the research unit two times during spring 2010:
on the first visit (January or March), fasting blood sam-
ples and spot urine samples were collected and subjects
were advised to fill in the study form, which included a
food frequency questionnaire (FFQ) concerning vitamin
D and calcium (Ca) intake, and a background question-
naire. All forms were checked by the researchers, and
additional information was requested if needed. Due to
missing data (e.g. background, blood sample, or geno-
type), the total number of subjects was 622 (421 women
and 201 men). Morbidly obese (BMI ≥ 40) and chronic-
ally ill individuals were excluded from the analysis.
Dietary intake and background data collection
The dietary intakes of vitamin D and Ca during the pre-
ceding month were evaluated using a validated FFQ cov-
ering over 70 foods [15]. The subjects completed a
questionnaire on medical history, medications and over-
all health, use of vitamin D and Ca supplements, and de-
tails about their physical activity. The average physical
activity was measured in minutes per week and included
all reported supervised and unsupervised exercise as well
as functional exercise. Holidays spent in sunny locations
during winter 2009–2010, from November 2009 to Janu-
ary 2010 (group 1) or from November 2009 to March
2010 (group 2), served as a measure of sunshine expos-
ure. Sunny locations were defined as locations with a
possibility for exposure to UV-irradiation. The persons
who used sunbed over ten times during 2008–2010 were
excluded from the analysis (N = 14).
Genotype analysis of the GC gene
SNPs covering the DBP gene region were selected from
the International HapMap Project database. The data
is available in International database 1000 Genomes
Browser (http://www.ncbi.nlm.nih.gov/variation/tools/
1000genomes/). We used the function “Download tag
SNP data” and selected three polymorphisms as represen-
tative of the polymorphisms in the DBP gene region.
These were polymorphisms that represented the linkage
disequilibrium structure of a region. Preference was given
to polymorphisms with high heterozygosity levels and
SNPs that are functional and have previously shown asso-
ciation in other studies. CEU population was used as a ref-
erence when selecting these three SNPs.
The selected SNPs were genotyped by using TaqMan
chemistry on an automatic sequence-detection instrument
(ABI Prism 7900HT, Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s protocol. Assays
and reagents were supplied by Applied Biosystems. Geno-
types were analyzed with SDS 2.3 and haplotypes with
HaploView 4.2. The following SNPs were genotyped:
rs4588 (Taqman SNP Assay ID: C___8278879_10), rs7041
(Taqman SNP Assay ID: C___3133594_30), and rs705124
(Taqman SNP Assay ID: C___8278822_10).
DBP analysis
DBP was isolated from plasma samples and protein con-
centrations were determined with a commercially avail-
able ELISA assay (Immundiagnostik AG, Bensheim,
Germany). This method uses polyclonal DBP antibodies.
Biochemistry
Twelve-hour fasting blood samples were collected on
the first visit. All samples were obtained between 7:30
and 9:15 a.m., and serum was extracted from blood by
centrifugation (except for whole-blood samples for DNA
isolation) and stored immediately after sampling at −20 °
C to −70 °C to await analysis. Serum Ca, albumin, and
creatinine were analyzed by a photometric method by
using a Konelab20 automatic analyzer (Thermo Clinical
Labsystems, Espoo, Finland). Inter and intra CV%s were
<4.6 for the above-mentioned analyses. S-25(OH)D con-
centrations were analyzed by using an IDS enzyme im-
munoassay kit (Immunodiagnostics Systems Ltd.,
Boldon, UK). Inter and intra CV%s were 2.7 and 3.2, re-
spectively. Serum PTH concentrations were analyzed by
using an immunoluminescence-based method (Immu-
lite1000, Siemens Healthcare Diagnostics, NY, USA). In-
ter CV% was 8.0 and intra CV% <5.5.
Calculation of free and bioavailable 25(OH)D
Calculation of free 25(OH)D was performed using the
following equation [1, 11]:
F½  ¼ T½ 
1þ KALB ALB½  þ KDBP DBP½ ð Þ
Where T and F are the total and free vitamin D con-
centrations, respectively, and KALB and KDBP are the
affinity constants for 25(OH)D with albumin and DBP.
When the diplotype- and haplotype-corrected free and
bioavailable 25(OH)D values were calculated, the affinity
constants of 25(OH)D with albumin and DBP were re-
placed with the genotype-specific affinity constants.
The affinity constant used for albumin was 6 × 105 and
for DBP 7 × 108. Haplotype-corrected free 25(OH)D
concentration was calculated by placing a haplotype-
specific affinity constant in the formula by Arnaud et al.
[6]. Diplotype-corrected free 25(OH)D concentrations
were calculated based on the affinity constants for
GC1S, GC1F, and GC2. The binding coefficients of the
diplotypes were calculated as the mean of the corre-
sponding two haplotypes according to Johnsen et al.
[10]. The diplotype-corrected affinity constants were as
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follows: 1S/1S = 6 × 108, 1S/2 = 4.8 × 108, 1F1F = 11.2 ×
108, 1 F/1S = 8.6 × 108, 1 F/2 = 7.4 × 108 and 2/2 = 3.6 +
108. Bioavailable 25(OH)D and the haplotype/diplotype-
corrected bioavailable 25(OH)D were calculated as a
sum of free 25(OH)D and albumin-bound 25(OH)D.
Statistical analyses
Descriptive data are reported as means ± SD. We used a
Chi-square test to assess whether DBP genotype distri-
butions were in Hardy-Weinberg equilibrium. Associa-
tions between variables of interest were tested with the
Pearson correlation. Logarithmic transformation was ap-
plied to non-Gaussian variables. If outliers were de-
tected, Spearman correlation was used instead.
ANCOVA analysis was used to test variation among the
GC genotypes in serum total, free, bioavailable, and
genotype-corrected 25(OH)D concentrations. Vitamin D
intake, S-PTH concentration, holidays in sunny loca-
tions, sex and BMI was used as covariates. ANCOVA
analysis was also applied to test the variation between
the GC genotypes and DBP as well as between the GC
genotypes and PTH. In the DBP analysis, sex and BMI
were used as covariates and in the PTH analysis,
25(OH)D and Ca intake were the covariates. Tests for
linear trend among the genotypes in the 25(OH)D, PTH,
and DBP concentrations were performed by using con-
trast analysis. In this analysis, the three genotypes of the
SNP 4588 were coded as −1, 0, and 1.
All calculations were performed using PASW Statistics
version 18.0.2 (IBM, Armonk, NY, USA). A p-value of
less than 0.05 was considered significant.
Results
Characteristics of participants
The background characteristics of all subjects are presented
in Table 1. Background characteristics stratified by geno-
types are presented in Additional file 1: Table S1. Women
and men differed significantly in height, weight, BMI,
history of smoking, serum albumin concentrations, and
amount of physical activity (Additional file 2: Table S2).
The mean total vitamin D intake was 15.1 μg/d, and in-
take from supplements was 7.2 μg/d. No significant differ-
ence was present in vitamin D intake among the
genotypes. The mean Ca intake was 1253 mg/d and intake
from supplements 87 mg/d. The mean daily vitamin D and
Ca intakes (including supplements) were in line with Nor-
dic recommendations for vitamin D and Ca intake [16].
The mean serum 25(OH)D concentration in the total
population was 56 nmol/L and the mean serum PTH
concentration 54.6 (±25) ng/L. The mean DBP concen-
tration was 368 (±88) mg/L. No significant correlation
was found between the 25(OH)D concentrations and the
DBP concentrations (r = −0.018, p = 0.678). A negative
correlation was present between S-PTH and total
25(OH)D (r = −0.235, p < 0.001). Similar negative corre-
lations were also observed between free and bioavailable
25(OH)D and S-PTH (r = −0.223, p < 0.001; r = −0.217,
p < 0.001). Total 25(OH)D correlated negatively with
BMI (r = −0.173, p < 0.001).
Genotype, haplotype, and allele distributions
The distribution of the GC genotypes was as follows:
64 % GC1/1, 31.5 % GC1/2, and 4.5 % GC2/2. When the
SNPs rs4588 and rs7041 were combined, they formed
six diplotypes with distributions of 47 % GC1S/1S, 25 %
GC1S/2, 2 % GC1F/1 F, 6 % GC1F/2, 16 % GC1F/1S,
and 4 % GC2/2. In addition, there were a few undetect-
able individuals that could have been representing some
of the rare diplotypes. Haplotype analysis (combining
rs4588 and rs7041) revealed three different haplotypes,
corresponding to the three GC protein isoforms GC1S,
GC1F, and GC2. The distribution of the haplotypes was
as follows: 88 % GCIS, 3.7 % GCIF, and 8.5 % GC2. The
distribution of the third SNP rs705124 was 61 % geno-
type 1, 34 % genotype 2, and 5 % genotype 3. The distri-
butions of the rs4588, rs7041, and rs705124 genotypes
were in accordance with Hardy-Weinberg equilibrium
(p = 0.73, 0.12, 0.80, respectively).
Table 1 Characteristics of all subjects
Variable N = 622
Men (%) 32
Women (%) 68
Age (years) 42 ± 3
Height (cm) 1.70 ± 0.1
Weight (kg) 76 ± 14
Body mass index (kg/m2) 26.2 ± 4.3
Calcium intake (mg/day) 1253 ± 530
Vitamin D intake (μg) 15.1 ± 13
S-25(OH)D (nmol/L) 55.7 ± 19.2
Free 25(OH)D (pmol/L) 12.2 ± 4.9
Bioavailable 25(OH)D (nmol/L) 4.80 ± 2.0
S-PTH (ng/L) 54.6 ± 25
S-DBP (mg/L) 368 ± 88
S-Albumin (g/L) 43.7 ± 3.0
All physical activity (min/week) 481 ± 372
History of regular smokinga (%) 46
Current Smokers:
Cigarettes per day
1–5 17 %
6 or more 83 %
Values are presented as mean ± SD
aat least one cigarette per day for 6 months
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Associations of GC genotypes with DBP, 25(OH)D, and
PTH concentrations
DBP concentrations in the diplotype and haplotype groups
differed from each other significantly (p = 0.039, 0.039, re-
spectively, overall ANCOVA analysis), one of the lowest
concentration being in persons with the GC2/2 genotype
(Fig. 1a). Serum 25(OH)D concentrations differed among
the SNP rs4588 genotypes (p = 0.031, ANCOVA) and also
between the six diplotypes of rs4588 and rs7041 combined
(Fig. 1b) (p = 0.033, ANCOVA), after adjustment for the
covariates S-PTH, vitamin D intake, sunlight exposure,
BMI and sex. Also PTH concentrations differed between
the diplotypes (p = 0.040), adjusted for 25(OH)D and
calcium intake and sex (Fig. 1c).
The difference in S-PTH between the haplotypes was
borderline significant (p = 0.078), and a linear trend was
present (p = 0.044) (Table 3). Among the SNP rs705124
genotypes, a difference between PTH concentrations
was observed (p = 0.016, ANCOVA, data not shown).
Concentrations of free and bioavailable 25(OH)D among
genotypes
Neither the concentration of free nor bioavailable
25(OH)D concentration differed among the diplo-/haplo-
types. However, when the values were genotype-corrected,
the highest concentration of free 25(OH)D was found in
diplotype 2/2 (p < 0.001, ANCOVA) and haplotype GC2
(p < 0.001). Similar differences were found among the bio-
available 25(OH)D concentrations (p < 0.001) (Fig. 1d, e,
Tables 2 and 3). The number of subjects in Tables 2 and 3
are presented as a range because the number varied de-
pending on the value analyzed.
Discussion
We found differences in the total, genotype-corrected free,
and bioavailable 25(OH)D concentrations and the DBP
concentrations among GC genotypes, indicating that the
biological response could possibly be modified by the
availability of 25(OH)D. Moreover, some genotypes with
a
d e
b c
Fig. 1 a Association of GC diplotypes with DBP concentrations (p = 0.039), b 25(OH)D concentrations (p = 0.033), c PTH concentrations (p = 0.040),
d serum free and diplotype-corrected free 25(OH)D concentrations (NS and p < 0.001, respectively), and e serum bioavailable and diplotype-
corrected bioavailable concentrations (NS and p < 0.001, respectively). The variables were adjusted for PTH, vitamin D intake, sunlight exposure,
sex and BMI (B,D,E) or for 25(OH)D and Ca intake (C) or for BMI and sex (A). Results are shown as estimated means ± SE, ANCOVA
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low 25(OH)D concentrations also had low PTH concen-
trations, which is contrary to the usual finding for this
relationship. Interestingly, the free and bioavailable
25(OH)D concentrations were high in these groups, which
could explain the low PTH concentration.
Previous studies have shown the critical role of GC
genotypes and serum GC protein concentration for vita-
min D metabolism [11, 12, 17, 18]. The 25(OH)D con-
centrations have been suggested to differ among DBP
phenotypes and genotypes. In this study, we wanted to
extend the observations to diplotypes and haplotypes.
We discovered a significant difference in 25(OH)D con-
centrations among the SNP rs4588 genotypes. A similar
difference was also found among the diplotypes when
two SNPs, rs4588 and rs7041, were combined. Among
the SNP rs4588, the lowest 25(OH)D concentration was
seen in individuals with the GC2/2 genotype and the
highest in individuals with GC1/1. Within diplotypes,
the difference was significant between genotypes 1S/2
and 1 F/2, the 25(OH)D concentration being lowest in
Table 2 Comparison of total 25(OH)D, free and diplotype-corrected free 25(OH)D, and PTH and DBP concentrations among the GC
diplotypes
GC diplotypes GC1S/1S GC 1S/2 GC 1S/1 F GC 1 F/1 F GC 1 F/2 GC 2/2
Dependent variable ANCOVA
p-value
S-25(OH)D (nmol/L) 55.9
(280)
± 0.99 51.9
(152)
± 1.34 50.2
(13)
± 4.6 55.1
(38)
± 2.7 58.6
(90)
± 1.7 52.5
(26)
± 3.3 0.033a
Free 25(OH)D (pmol/L) 12.2
(236)
± 0.29 11.7
(121)
± 0.40 10.1
(10)
± 1.40 11.6
(31)
± 0.80 12.5
(78)
± 0.50 12.6
(24)
± 0.90 0.491a
Diplotype corrected free 25(OH)D
(pmol/L)d
14.1
(236)
± 0.30 6.06
(121)
± 0.42 6.40
(10)
± 1.47 9.65
(31)
± 0.85 12.2
(78)
± 0.53 23.1
(24)
± 0.95 <0.001a
Bioavailable 25(OH)D (nmol/L) 4.81
(236)
± 0.12 4.70
(121)
± 0.16 3.97
(10)
± 0.57 4.62
(31)
± 0.33 5.01
(78)
± 0.20 5.07
(24)
± 0.37 0.469a
Diplotype corrected bioavailable
25(OH)D (nmol/L)d
5.60
(235)
± 0.13 2.44
(121)
± 0.17 2.50
(10)
± 0.60 3.86
(31)
± 0.35 4.92
(78)
± 0.22 9.25
(24)
± 0.39 <0.001a
S-DBP (mg/L) 369
(238)
± 5.55 360
(121)
± 7.78 364
(10)
± 27.1 388(31) ± 15.4 380
(78)
± 9.7 321
(24)
± 17.5 0.039b
S-PTH (ng/L) 55.0
(289)
± 1.44 56.8
(157)
± 1.96 60.6
(13)
± 6.78 45.6
(38)
± 3.96 57.5
(92)
± 2.55 46.0
(26)
± 4.79 0.040c
Diplotype means were compared with ANCOVA ± SE. The values are adjusted estimates from ANCOVA. N in parenthesis
Significant p-values are indicated in bold
aAdjusted for age, S-PTH, vitamin D intake, sunlight exposure and sex
bAdjusted for BMI and sex
cS-25(OH)D, Ca intake
GC diplotype was used as a fixed factor
dDiplotype-corrected free and bioavailable 25(OH)D values were calculated by placing a diplotype-specific binding coefficient into the free and bioavailable formulae
Table 3 Comparison of 25(OH)D, free- and diplotype-corrected free 25(OH)D, and DBP and PTH concentrations among the GC
haplotypes
GC haplotype GC1S GC1F GC2 ANCOVA p-value
Dependent variable
S-25(OH)D (nmol/L) 57.1 (281) ± 1.04 50.6 (13) ± 4.9 52.7 (25) ± 3.53 0.231a
Free 25(OH)D (pmol/L) 12.5 (237) ± 0.30 10.1 (10) ± 1.46 12.6 (23) ± 0.97 0.280a
Diplotype corrected free 25(OH)D (pmol/L)e 14.2 (237) ± 0.35 6.30 (10) ± 1.70 22.8 (23) ± 1.12 <0.001a
Bioavailable 25(OH)D (nmol/L) 4.92 (237) ± 0.12 3.98 (10) ± 0.59 5.01 (23) ± 0.39 0.261a
Diplotype corrected bioavailable 25(OH)D (nmol/L)e 5.61 (237) ± 0.14 2.47 (10) ± 0.68 9.15 (23) ± 0.45 <0.001a
S-DBP (mg/L) 369 (240) ± 5.60 364 (10) ± 27.4 320 (23) ± 18.1 0.039b
S-PTH (ng/L) 54.5 (283) ± 1.39 60.7 (13) ± 6.52 44.7 (25) ± 4.70 0.078cd
Haplotype means were compared with ANCOVA ± SE. The values are adjusted estimates from ANCOVA. N in parenthesis
Significant p-values are indicated in bold
aAdjusted for age, S-PTH, vitamin D intake, sunlight exposure and sex
bAdjusted for BMI and sex
cS-25(OH)D, Ca intake
da linear trend, p = 0.044
GC haplotype was used as a fixed factor
eHaplotype-corrected free and bioavailable 25(OH)D values were calculated by placing a haplotype-specific binding coefficient into the free and bioavailable formulae
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genotype 1S/1 F and highest in 1 F/2. Our results are in
line with earlier studies [18–21]. Most of the studies
have focused on the two common SNPs rs4588 and
rs7041, but they are seldom used in combination to form
diplotypes.
In this study, the DBP concentrations varied signifi-
cantly among the GC genotypes. The lowest DBP concen-
tration was found in GC2/2 and the highest in GC1/1. In
diplotypes, the highest concentration was found in GC1F/
1 F and the lowest in GC2/2. A significant difference in
DBP concentration emerged between GC1F/2 and GC2/2.
Also haplotype-corrected DBP values differed; the highest
value was observed in GC1S and the lowest in GC2. Vari-
ation in DBP concentrations based on DBP genotypes has
been reported also in previous studies, but the results have
not been consistent [11, 18, 21]. Powe et al. [11] reported
that the T-allele at rs7041 was associated with decreased
concentrations of DBP, and allele A at rs4588 was associ-
ated with higher DBP, after accounting for rs7041. In a
study conducted with African American and Caucasian
American subjects, GC1S homozygotes had the highest
DBP concentration, GC2 had an intermediate concentra-
tion, and GC1F had the lowest concentration [18]. Similar
to our results, a Danish study observed that GC2 homozy-
gotes generally had lower DBP concentrations than the
other genotypes [21].
However, criticism has been directed at some of the
measurement protocols used by earlier studies for deter-
mining the DBP concentration. It has been suggested
that studies based on monoclonal antibodies [11, 18]
may be inaccurate because the assay might not have
equal affinity for all genotypes. The use of polyclonal
antibodies instead has been proposed [22].
Based on the free hormone hypothesis, the free fractions
could correlate better with biological actions of vitamin D
than the total 25(OH)D [9]. In order to test the free and
the bioavailable hypotheses, we calculated the concentra-
tions of unbound “free” 25(OH)D and bioavailable
25(OH)D. A Norwegian study found that adjusting for
DBP phenotype-specific (SNPs rs4588 and rs7041 com-
bined) binding coefficients affected the calculated free and
bioavailable concentrations by up to 37.5 % [10]. Thus,
additional genotype adjustment was made for diplotype-
and haplotype-specific binding coefficients. In our study,
serum free or bioavailable 25(OH)D concentrations did
not differ significantly between the genotypes. However,
after adjustment for diplotype-specific binding coefficients
a significant difference emerged in free and bioavailable
values among the haplotypes and diplotypes. The highest
concentrations of free and bioavailable 25(OH)D were
found in GC 2/2 and the lowest in haplotype GC1F and
diplotypes GC1S/2, GC1S/2, and 1S/1 F. Powe et al. [11]
stated that genetic polymorphism explained almost 10 %
of the variation in 25(OH)D levels. In their study, the T-
allele at rs7041 was associated with decreased levels of
vitamin D-binding protein in both black and white Ameri-
cans. In white individuals, the A-allele at rs4588 was asso-
ciated with decreased levels of total 25(OH)D.
An inverse association between 25(OH)D and PTH
has been found in numerous studies. PTH has therefore
been suggested to be used as a health outcome reference
for optimal vitamin D status. However, the cut-off values
for PTH and 25(OH)D differ considerably among stud-
ies, making this very difficult. Moreover, large variation
exists in PTH at specific 25(OH)D concentrations [13].
In our previous study in Finnish children and adoles-
cents, we observed that GC2 phenotype was associated
with the lowest 25(OH)D concentrations and that there
was an inverse association between 25(OH)D and PTH
within the genotypes [23]. Interestingly, the GC2/2 geno-
type, which had the lowest 25(OH)D, also had the lowest
PTH concentration, which is contrary to the association
in general. Here, we found differences in PTH concen-
trations among the diplotypes and a similar linear trend
in haplotypes. GC2/2, with the second lowest 25(OH)D
among diplotypes, also had the lowest PTH.
In accord with our finding, a Danish study observed
that rs4588-AA carriers had the lowest prevalence of
25(OH)D > 50 nmol/L in a vitamin D fortification group,
but in the control group the SNP rs4588 carriers had the
lowest prevalence of low vitamin D status. They state
that this may suggest that rs4588 carriers have low, yet
stable 25(OH)D concentrations. The rs4588-AA geno-
type had also lower PTH levels and 25(OH)D concentra-
tions relative to rs4588-CC or rs4588-CA carriers [20].
In comparison, the genetic variance in GC significantly
contributed to circulating DBP as well as to 25(OH)D in
a study in North American children [24]. However, in
that study both total and free 25(OH)D correlated in-
versely with PTH, and this correlation was independent
of DBP genotype. Interestingly, we also noted a differ-
ence in PTH concentrations among SNP rs705124,
which has not been reported in earlier studies. Thus, our
results emphasize the importance of the genetic vari-
ation in DBP in vitamin D and mineral metabolism.
In addition to renal production of 1,25(OH)2D3, there is
local production in non-renal tissues. Based on our previ-
ous findings and the results in this paper, we hypothesize
that free 25(OH)D may enter the parathyroid glands and
might be converted locally to 1,25(OH)2D3 with the help
of cytochrome p450 27B1 enzyme (CYP27B1) in the cell.
The higher amount of 1,25(OH)2D3 could suppress the
production of PTH and explain the lower concentration
of PTH with the GC2/2 genotype. Our results support
those of Ritter et al. [25], who demonstrated the presence
of 25(OH)D 1-alpha-hydroxylase (1alpha-OHase) in
cultured bovine parathyroid cells and showed that the en-
zyme was functionally active, converting 25(OH)D to 1-
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hydroxylated metabolites and inducing the major enzyme
involved in the degradation of calcitriol, 25(OH)D 24-
hydroxylase (24-OHase, CYP24A1). This together with
the fact that vitamin D receptor (VDR) was expressed in
the cells suggests an autocrine/paracrine function for
locally produced 1,25(OH)2D3. They showed that
25(OH)D suppressed the production of PTH without the
involvement of conversion to 1,25(OH)2D3, but possibly
by interaction with VDR. The experiments were done in
serum-free medium, indicating that no DBP was needed
for the internalization and that the effects could be due to
free 25(OH)D. Therefore, local production of 1alpha-
OHase suggests an autocrine/paracrine role in regulating
parathyroid function and may mediate, in part, the
suppression of PTH by calcium and FGF-23 [25].
A Canadian study concluded that the biological effect of
vitamin D on PTH concentration is mainly independent
of DBP concentrations [12]. Another North-American
study reported that genetic variance in GC significantly
contributed to circulating DBP as well as to 25(OH)D
[24]. However, both total and free 25(OH)D were corre-
lated inversely with PTH, and this correlation was inde-
pendent of DBP genotype. This reinforces our hypothesis
that free and bioavailable 25(OH)D may be good
biomarkers of vitamin D status and action in cells than
serum 25(OH)D per se.
One of the limitations of this study is that it was not
designed to demonstrate a difference in the concentra-
tion of 25(OH)D, DPB, or PTH in the different geno-
types. The study derives from a larger study focusing on
phosphorus intake and bone outcomes. The sample size
was calculated to find a 4 % difference (standard devi-
ation, SD-0.050 g/cm2) in distal radius bone mineral
density between the highest and lowest phosphorus in-
take tertiles.
Other limitation of this study is that the affinity con-
stants of DBP by Arnauld et al. [6] are derived by experi-
mental evidence from one individual’s human serum
sample. It has not been investigated whether post-
translational modification of Gc may influence affinity
for vitamin D metabolites. In addition, the Gc affinity
constant for 25(OH)D3 in published literature ranges by
several orders of magnitude from 1.9 × 10-10 to 1.5 to
10–8 [1]. It is also known that Gc protein circulates sev-
eral fold above 25(OH)D concentrations, with only ap-
proximately 5 % of circulating Gc protein occupied by
vitamin D metabolites.
As we do not have the full protein sequence, we can-
not be certain whether we have some of the other Gc-
isoforms. According to Arnaud’s analysis, binding affinity
of these more rare isoforms may vary as much as 12
fold. Nevertheless, the other isoforms are quite rare.
Arnauld’s affinity constants are estimated for 25(OH)D3
and not for 25(OH)D2 but this is not a problem for the
interpretation of the results as vitamin D2 is not found
in foods and only in a few supplements in Finland as
food is fortified with vitamin D3 and most of the supple-
ments are vitamin D3.
Conclusions
Our findings indicate that genetic polymorphisms of
DBP and free and bioavailable concentrations of
25(OH)D may be of relevance when vitamin D status
and vitamin D metabolism are evaluated. Important
findings were the relationships between PTH and free
and bioavailable 25(OH)D and genetic variation of DBP.
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